In December, Bothell-based MDRNA, Inc. was granted tentative approval by the U.S. Food and Drug Administration for the use of it new generic calcitonin-salmon nasal spray in the treatment of osteoporosis. Full FDA approval would follow a 180-day exclusivity period ending in June.
MDRNA’s calcitonin-salmon nasal spray, a legacy product developed by MDRNA in the early 2000s, is the generic equivalent of Miacalcin, marketed by Novartis Pharmaceuticals Corp. U.S. sales of Miacalcin were approximately $147 million in 2007. For more information, visit www.mdrnainc.com.
Talk to us
> Give us your news tips.
> Send us a letter to the editor.
> More Herald contact information.
